On the other hand, Zecchin and colleagues clearly demonstrated that proteasome inhibitors possess a significant selectivity toward BRAFV600E-mutant colorectal cancer cells as a consequence of persistent BRAF signaling and a nononcogenic addiction to the proteasome function in those cells [57]. This evidence concerns the gene BRAF and colorectal cancer.